In a filing, Axsome Therapeutics Inc revealed its Officer Murdock Hunter R. acquired Company’s shares for reported $0.77 million on Jun 16 ’25. In the deal valued at $102.42 per share,7,500 shares were bought.
Then, Jacobson Mark L. sold 25,000 shares, generating $2,761,000 in total proceeds. Upon selling the shares at $110.44, the Chief Operating Officer now owns 5,783 shares.
Before that, Jacobson Mark L. bought 25,000 shares. Axsome Therapeutics Inc shares valued at $2,760,894 were divested by the Officer at a price of $110.44 per share.
Oppenheimer initiated its Axsome Therapeutics Inc [AXSM] rating to an Outperform in a research note published on June 03, 2025; the price target was $185. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Deutsche Bank began covering AXSM with “Buy” recommendation on February 11, 2025. Mizuho maintained its rating on December 31, 2024. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Monday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock fall -2.32% to $101.69. Over the last five days, the stock has lost -7.45%. Axsome Therapeutics Inc shares have risen nearly 20.19% since the year began. Nevertheless, the stocks have risen 42.12% over the past one year. While a 52-week high of $139.13 was reached on 02/21/25, a 52-week low of $71.15 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 100.38, which if violated will result in even more drops to 99.06. On the upside, there is a resistance level at 103.64. A further resistance level may holdings at 105.58.
The most recent change occurred on September 03, 2024 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $140 price target.
